PortalPublikationenAbklärung und Therapie von Refluxbeschwerden

Abklärung und Therapie von Refluxbeschwerden

Standard

Abklärung und Therapie von Refluxbeschwerden. / Morgner-Miehlke, A; Koop, H; Blum, A L; Hermans, M-L; Miehlke, S; Labenz, J.

in: Z GASTROENTEROL, Jahrgang 44, Nr. 5, 05.2006, S. 399-410.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Morgner-Miehlke, A, Koop, H, Blum, AL, Hermans, M-L, Miehlke, S & Labenz, J 2006, 'Abklärung und Therapie von Refluxbeschwerden', Z GASTROENTEROL, Jg. 44, Nr. 5, S. 399-410. https://doi.org/10.1055/s-2006-926619

APA

Morgner-Miehlke, A., Koop, H., Blum, A. L., Hermans, M-L., Miehlke, S., & Labenz, J. (2006). Abklärung und Therapie von Refluxbeschwerden. Z GASTROENTEROL, 44(5), 399-410. https://doi.org/10.1055/s-2006-926619

Vancouver

Morgner-Miehlke A, Koop H, Blum AL, Hermans M-L, Miehlke S, Labenz J. Abklärung und Therapie von Refluxbeschwerden. Z GASTROENTEROL. 2006 Mai;44(5):399-410. https://doi.org/10.1055/s-2006-926619

Bibtex

@article{1e9386625a8a49c297e0d049a15a2851,
title = "Abkl{\"a}rung und Therapie von Refluxbeschwerden",
abstract = "The current guidelines of the German Society for Digestive Diseases (DGVS) endoscopy recommends for patients representing with reflux symptoms. In daily routine as well as in Guidelines from other countries and international guidelines, however, a symptom-based strategy for the management of patients with reflux disease is favoured. Since either strategies is dependent on specific clinical findings, neither can be recommended. The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI). However, most patients with characteristic reflux symptoms without any alarm symptoms and/or other risk factors can be safely managed with a symptom-based strategy in acute and long-term care.",
keywords = "Adenocarcinoma, Anti-Ulcer Agents, Barrett Esophagus, Diagnosis, Differential, Disease Progression, Endoscopy, Digestive System, Esophageal Neoplasms, Esophagitis, Peptic, Gastroesophageal Reflux, Humans, Long-Term Care, Practice Guidelines as Topic, Proton Pump Inhibitors, Risk Factors, Treatment Outcome, English Abstract, Journal Article",
author = "A Morgner-Miehlke and H Koop and Blum, {A L} and M-L Hermans and S Miehlke and J Labenz",
year = "2006",
month = may,
doi = "10.1055/s-2006-926619",
language = "Deutsch",
volume = "44",
pages = "399--410",
journal = "Z GASTROENTEROL",
issn = "0044-2771",
publisher = "Karl Demeter Verlag GmbH",
number = "5",

}

RIS

TY - JOUR

T1 - Abklärung und Therapie von Refluxbeschwerden

AU - Morgner-Miehlke, A

AU - Koop, H

AU - Blum, A L

AU - Hermans, M-L

AU - Miehlke, S

AU - Labenz, J

PY - 2006/5

Y1 - 2006/5

N2 - The current guidelines of the German Society for Digestive Diseases (DGVS) endoscopy recommends for patients representing with reflux symptoms. In daily routine as well as in Guidelines from other countries and international guidelines, however, a symptom-based strategy for the management of patients with reflux disease is favoured. Since either strategies is dependent on specific clinical findings, neither can be recommended. The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI). However, most patients with characteristic reflux symptoms without any alarm symptoms and/or other risk factors can be safely managed with a symptom-based strategy in acute and long-term care.

AB - The current guidelines of the German Society for Digestive Diseases (DGVS) endoscopy recommends for patients representing with reflux symptoms. In daily routine as well as in Guidelines from other countries and international guidelines, however, a symptom-based strategy for the management of patients with reflux disease is favoured. Since either strategies is dependent on specific clinical findings, neither can be recommended. The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI). However, most patients with characteristic reflux symptoms without any alarm symptoms and/or other risk factors can be safely managed with a symptom-based strategy in acute and long-term care.

KW - Adenocarcinoma

KW - Anti-Ulcer Agents

KW - Barrett Esophagus

KW - Diagnosis, Differential

KW - Disease Progression

KW - Endoscopy, Digestive System

KW - Esophageal Neoplasms

KW - Esophagitis, Peptic

KW - Gastroesophageal Reflux

KW - Humans

KW - Long-Term Care

KW - Practice Guidelines as Topic

KW - Proton Pump Inhibitors

KW - Risk Factors

KW - Treatment Outcome

KW - English Abstract

KW - Journal Article

U2 - 10.1055/s-2006-926619

DO - 10.1055/s-2006-926619

M3 - SCORING: Zeitschriftenaufsatz

C2 - 16688658

VL - 44

SP - 399

EP - 410

JO - Z GASTROENTEROL

JF - Z GASTROENTEROL

SN - 0044-2771

IS - 5

ER -